A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy

Protocol No
MIRATI-516-005
Principal Investigator
Smitha Menon
Phase
III
Summary
This study will evaluate whether the combination of immune system stimulation caused by sitravatinib and improved recognition of tumor cells caused by nivolumab results in more anti tumor activity (tumor shrinkage) than treatment with docetaxel.Other objectives of the study include evaluating the safety of sitravatinib in combination with nivolumab, assessing how quickly sitravatinib is absorbed into the blood stream and how fast it is removed, and evaluating your health-related quality of life. Several laboratory tests will be performed using samples of tumor tissue or blood to understand how and why the drugs may work together in the treatment of lung cancer.
Description
Sitravatinib + Nivolumab vs Docetaxel in Patients with Advanced Non-Squamous NSCLC
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: